CS
DFTX

Credit Suisse’s Definium Therapeutics DFTX Stock Holding History

Credit Suisse’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22,306
Closed -$78K – 4065
2022
Q3 		$78K Buy
22,306
+990
+5% +$9.5K ﹤0.01% 3481
2022
Q2 		$204K Buy
21,316
+2,712
+15% +$34.3K ﹤0.01% 3316
2022
Q1 		$309K Buy
18,604
+4,265
+30% +$74K ﹤0.01% 3212
2021
Q4 		$297K Sell
14,339
-1,483
-9% -$47.3K ﹤0.01% 4116
2021
Q3 		$553K Sell
15,822
-47
-0.3% -$2.03K ﹤0.01% 3743
2021
Q2 		$822K Buy
+15,869
New +$833K ﹤0.01% 3530

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Credit Suisse's DFTX Position: Q4 2022 in Review

Credit Suisse sold out of Definium Therapeutics (DFTX) in Q4 2022, closing a stake of 22,306 shares — an estimated $78K sold.

Credit Suisse first reported a position in DFTX in Q2 2021 and held it in 6 quarters. The position peaked at $822K in Q2 2021. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Credit Suisse reported no remaining Definium Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 22,306 Definium Therapeutics shares in Q4 2022, an estimated $78K.
  • Credit Suisse first reported a position in Definium Therapeutics in Q2 2021 and held it in 6 quarters.
  • Credit Suisse's Definium Therapeutics position peaked at $822K in Q2 2021.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.